These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

821 related articles for article (PubMed ID: 31538520)

  • 1. Prodrugs in combination with nanocarriers as a strategy for promoting antitumoral efficiency.
    Lin MH; Hung CF; Hsu CY; Lin ZC; Fang JY
    Future Med Chem; 2019 Aug; 11(16):2131-2150. PubMed ID: 31538520
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prodrug-based nanoparticulate drug delivery strategies for cancer therapy.
    Luo C; Sun J; Sun B; He Z
    Trends Pharmacol Sci; 2014 Nov; 35(11):556-66. PubMed ID: 25441774
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Nanoparticles as delivery carriers for anticancer prodrugs.
    Fang JY; Al-Suwayeh SA
    Expert Opin Drug Deliv; 2012 Jun; 9(6):657-69. PubMed ID: 22507134
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Fighting the resistance: rejuvenating anticancer platinum-based drugs.
    O'Hare A
    Nanomedicine (Lond); 2012 Jul; 7(7):947-8. PubMed ID: 23019670
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Smart nanocarriers for enzyme-activated prodrug therapy.
    Abo Qoura L; Morozova E; Ramaa СS; Pokrovsky VS
    J Drug Target; 2024 Nov; 32(9):1029-1051. PubMed ID: 39045650
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Lipid prodrug nanocarriers in cancer therapy.
    Mura S; Bui DT; Couvreur P; Nicolas J
    J Control Release; 2015 Jun; 208():25-41. PubMed ID: 25617724
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Formulation optimization of an ephrin A2 targeted immunoliposome encapsulating reversibly modified taxane prodrugs.
    Huang ZR; Tipparaju SK; Kirpotin DB; Pien C; Kornaga T; Noble CO; Koshkaryev A; Tran J; Kamoun WS; Drummond DC
    J Control Release; 2019 Sep; 310():47-57. PubMed ID: 31400383
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dimeric prodrug-based nanomedicines for cancer therapy.
    Li S; Shan X; Wang Y; Chen Q; Sun J; He Z; Sun B; Luo C
    J Control Release; 2020 Oct; 326():510-522. PubMed ID: 32721523
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Recent advances in prodrug-based nanoparticle therapeutics.
    Chen KJ; Plaunt AJ; Leifer FG; Kang JY; Cipolla D
    Eur J Pharm Biopharm; 2021 Aug; 165():219-243. PubMed ID: 33979661
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Quantitative and high drug loading of self-assembled prodrug with defined molecular structures for effective cancer therapy.
    Tang J; Zeng Z; Yan J; Chen C; Liu J; Feng X
    J Control Release; 2019 Aug; 307():90-97. PubMed ID: 31185233
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Biodegradable and pH-Responsive Acetalated Dextran (Ac-Dex) Nanoparticles for NIR Imaging and Controlled Delivery of a Platinum-Based Prodrug into Cancer Cells.
    Braga CB; Perli G; Becher TB; Ornelas C
    Mol Pharm; 2019 May; 16(5):2083-2094. PubMed ID: 30901218
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Somatostatin receptor-mediated specific delivery of paclitaxel prodrugs for efficient cancer therapy.
    Huo M; Zhu Q; Wu Q; Yin T; Wang L; Yin L; Zhou J
    J Pharm Sci; 2015 Jun; 104(6):2018-2028. PubMed ID: 25820241
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Chitosan derivatives functionalized dual ROS-responsive nanocarriers to enhance synergistic oxidation-chemotherapy.
    Liao JX; Huang QF; Li YH; Zhang DW; Wang GH
    Carbohydr Polym; 2022 Apr; 282():119087. PubMed ID: 35123755
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Nanoassemblies containing a fluorouracil/zidovudine glyceryl prodrug with phospholipase A2-triggered drug release for cancer treatment.
    Jin Y; Yang F; Du L
    Colloids Surf B Biointerfaces; 2013 Dec; 112():421-8. PubMed ID: 24036626
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dimeric Prodrug Self-Delivery Nanoparticles with Enhanced Drug Loading and Bioreduction Responsiveness for Targeted Cancer Therapy.
    He X; Cai K; Zhang Y; Lu Y; Guo Q; Zhang Y; Liu L; Ruan C; Chen Q; Chen X; Li C; Sun T; Cheng J; Jiang C
    ACS Appl Mater Interfaces; 2018 Nov; 10(46):39455-39467. PubMed ID: 30362704
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cargo-Free Nanomedicine with pH Sensitivity for Codelivery of DOX Conjugated Prodrug with SN38 To Synergistically Eradicate Breast Cancer Stem Cells.
    Sun N; Zhao C; Cheng R; Liu Z; Li X; Lu A; Tian Z; Yang Z
    Mol Pharm; 2018 Aug; 15(8):3343-3355. PubMed ID: 29923726
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Methotrexate-based amphiphilic prodrug nanoaggregates for co-administration of multiple therapeutics and synergistic cancer therapy.
    Hou M; Gao YE; Shi X; Bai S; Ma X; Li B; Xiao B; Xue P; Kang Y; Xu Z
    Acta Biomater; 2018 Sep; 77():228-239. PubMed ID: 30006314
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Injectable Drug-Loaded Nanocarriers for Lung Cancer Treatments.
    Yu HP; Aljuffali IA; Fang JY
    Curr Pharm Des; 2017; 23(3):481-494. PubMed ID: 28292243
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Carrier-free nanoparticles of cathepsin B-cleavable peptide-conjugated doxorubicin prodrug for cancer targeting therapy.
    Shim MK; Park J; Yoon HY; Lee S; Um W; Kim JH; Kang SW; Seo JW; Hyun SW; Park JH; Byun Y; Kwon IC; Kim K
    J Control Release; 2019 Jan; 294():376-389. PubMed ID: 30550940
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Exploiting Enzyme Alterations in Cancer for Drug Activation, Drug Delivery, and Nanotherapy.
    Hayashi JY; Tamanoi F
    Enzymes; 2017; 42():153-172. PubMed ID: 29054269
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 42.